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Abstract
Objectives To determine whether the receipt of chemotherapy among
terminally ill cancer patients months before death was associated with
patients’ subsequent intensive medical care and place of death.
Design Secondary analysis of a prospective, multi-institution, longitudinal
study of patients with advanced cancer.
Setting Eight outpatient oncology clinics in the United States.
Participants 386 adult patients with metastatic cancers refractory to at
least one chemotherapy regimen, whom physicians identified as
terminally ill at study enrollment and who subsequently died.
Main outcome measures Primary outcomes: intensive medical care
(cardiopulmonary resuscitation, mechanical ventilation, or both) in the
last week of life and patients’ place of death (for example, intensive care
unit). Secondary outcomes: survival, late hospice referrals (≤1 week
before death), and dying in preferred place of death.
Results 216 (56%) of 386 terminally ill cancer patients were receiving
palliative chemotherapy at study enrollment, a median of 4.0 months
before death. After propensity score weighted adjustment, use of
chemotherapy at enrollment was associated with higher rates of
cardiopulmonary resuscitation, mechanical ventilation, or both in the last
week of life (14% v 2%; adjusted risk difference 10.5%, 95% confidence
interval 5.0% to 15.5%) and late hospice referrals (54% v 37%; 13.6%,
3.6% to 23.6%) but no difference in survival (hazard ratio 1.11, 95%
confidence interval 0.90 to 1.38). Patients receiving palliative
chemotherapy were more likely to die in an intensive care unit (11% v
2%; adjusted risk difference 6.1%, 1.1% to 11.1%) and less likely to die
at home (47% v 66%; −10.8%, −1.0% to −20.6%), compared with those
who were not. Patients receiving palliative chemotherapy were also less
likely to die in their preferred place, compared with those who were not
(65% v 80%; adjusted risk difference −9.4%, −0.8% to −18.1%).
Conclusions The use of chemotherapy in terminally ill cancer patients
in the last months of life was associated with an increased risk of
undergoing cardiopulmonary resuscitation, mechanical ventilation or
both and of dying in an intensive care unit. Future research should
determine the mechanisms by which palliative chemotherapy affects
end of life outcomes and patients’ attainment of their goals.
Introduction
Chemotherapy is used to treat metastatic cancer, with the goal
of palliating symptoms and improving survival. Between 20%
and 50% of patients with incurable cancers receive
chemotherapy within 30 days of death,
1 2 despite growing
concerns that it may not be effective. Recently, the American
Society for Clinical Oncology identified end of life
chemotherapy as one of the “top five” practices that could
improve patients’ care and reduce costs, if stopped.
3 Deciding
when to discontinue chemotherapy is often challenging,
however,givenlimiteddataonwhetherchemotherapyishelpful
or harmful in the final months of life.
2 4 5
Research suggests that the use of chemotherapy within two
weeks of death is associated with lower rates of hospice use,
6 7
but only 6.2% of patients receive chemotherapy this late.
8 Most
decisionsabouttreatmentoccurmonthsbeforedeath,whendata
toguidedecisionmakingaboutchemotherapyaremorelimited.
Forexample,inarandomizedcontrolledstudycomparingearly
palliative care integrated with oncology care versus standard
oncology care among patients newly diagnosed as having
metastaticlungcancer,Greeretalfoundthat62%ofallenrolled
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Research
RESEARCHpatients received chemotherapy within two months of death.
9 10
However, patients who received concurrent palliative and
oncologic care stopped intravenous chemotherapy an average
of two months earlier than did those in the standard oncology
group but had a longer median overall survival and were more
likely to receive at least one week of hospice services.
9 10 To
our knowledge, however, Greer at al’s study and others have
not specifically examined whether the use of chemotherapy in
the months leading up to the patient’s death is associated with
thesubsequentreceiptofintensivemedicalcareinthelastweek
of life or death in an intensive care unit.
In this secondary analysis of Coping with Cancer data,
11 we
sought to determine whether terminally ill cancer patients who
were receiving chemotherapy at study enrollment were more
likely to receive intensive medical care in the last week of life
anddieinanintensivecareunit,comparedwiththosewhowere
not. We hypothesized that palliative chemotherapy would be
associated with more intensive medical care (for example,
cardiopulmonaryresuscitation,mechanicalventilation,orboth)
and late referrals to a hospice, as chemotherapy is often an
exclusion criterion for hospice admission,
12 13 and oncologists
expressreluctanceaboutdiscussingadvancecareplanningwhile
prescribing chemotherapy.
14-16 Similarly, we expected that
patients receiving palliative chemotherapy would be less likely
to die where they wanted to, as oncologists often delay
discussingpatients’preferredsiteofdeath,comparedwithother
non-cancer specialists.
14
Methods
Coping with Cancer was a federally funded, prospective,
longitudinal, multi-institution cohort study of terminally ill
cancer patients and their informal caregivers, which was
designed to examine how psychosocial factors influence
patients’ medical care and caregivers’ adjustment to
bereavement.
11Of917eligiblepatients,638(69.6%)consented
and enrolled in Coping with Cancer. The three most common
reasons for non-participation were “not interested” (n=120),
“other” (n=69), and “caregiver refuses” (n=37). Participants
were more likely than non-participants to be Hispanic (12%
(75/638) v 6% (16/279), P=0.006), but otherwise did not differ
by sociodemographic characteristics.
This report describes 386 patients who were recruited between
October 2002 and February 2008 and died during the course of
the study, such that we could analyze their end of life medical
care. We excluded participants in clinical trials (n=37), as their
treatment preferences and therapeutic expectations often differ
from those of patients receiving standard chemotherapy or
supportivecare.
17PatientswhohaddiedasofFebruary28,2008
did not differ significantly in type of cancer or receipt of
chemotherapyfromparticipantswholived.However,decedents
had worse performance status, more symptoms, and greater
awareness of terminal illness and were more likely to be male,
unmarried, uninsured, less educated, younger, and non-white
(all P<0.05).
Participating sites included Yale Cancer Center, the Veterans
AffairsConnecticutHealthcareSystemComprehensiveCancer
Clinics,theParklandHospitalPalliativeCareService,Simmons
ComprehensiveCancerCenter,MassachusettsGeneralHospital,
Dana-FarberCancerInstitute,MemorialSloanKetteringCancer
Center, and New Hampshire Oncology-Hematology. The
Dana-Farber/Harvard Cancer Center’s Office for Human
ResearchStudiescoordinatedthestudy,andallpatientsprovided
written informed consent.
Patientswereeligibletoparticipateiftheyhadmetastaticcancer
thathadprogressedthroughatleastonechemotherapyregimen,
had a physician formulated prognosis of six months or less to
live,wereagedatleast20years,hadaninformalcaregiver,and
wereassessedbyclinicstaffandinterviewerashavingadequate
stamina to complete the interview. We excluded
patient-caregiver dyads in which either the patient or the
caregiver refused to participate, met criteria for dementia or
delirium (by neurobehavioral cognitive status examination), or
did not speak either English or Spanish.
Patients participated in a baseline interview in English or
Spanish for a $25 (£15; €18) payment at a time that was close
to when decisions about chemotherapy were being made. We
reviewed medical charts at the time of study enrollment and
recorded current use of chemotherapy. Research assistants
confirmed patients’ performance status and prognosis of six
months or less with physicians. We did not record the number
and length of previous and subsequent treatments. After each
patient’s death, we conducted a chart review and postmortem
interview with the patient’s caregivers to confirm the medical
care received at the end of life, the patient’s place of death, and
whether the patient died in his or her preferred place of death.
Main outcome measures
The primary outcomes were end of life treatment and location
of death. We determined use of intensive interventions in the
last week of life (that is, cardiopulmonary resuscitation,
mechanicalventilation,orboth)andlocationofdeath(intensive
care unit, hospital, nursing home, inpatient hospice, or home)
through a medical chart review and interviews with caregivers.
Secondary outcome measures
Survival—We abstracted the time from study enrollment to
death from medical charts.
Latehospicereferrals—Wedeterminedthedurationofhospice
services through chart review and interviews with caregivers.
Wedefinedlatereferralstoahospiceasoneweekorlessbefore
death.
11
Attainment of preferred place of death—In postmortem
interviews, we asked caregivers, “Do you think that the place
ofdeathwaswherethepatientwouldhavemostwantedtodie?”
Patients whose caregivers responded “yes” were designated as
having died where they wanted to.
Primary independent variable of interest
We reviewed medical charts on study enrollment to determine
whether patients were receiving chemotherapy, radiation, pain
management, or treatment on a clinical trial at the time of
enrollment.Patientsreceivingchemotherapyasanypartoftheir
treatment, outside of a clinical trial, were included in the
chemotherapy group.
Additional covariates measured at baseline
Sociodemographiccharacteristics—Patientsreportedsex,age,
maritalstatus,race/ethnicity,religion,healthinsurancecoverage,
and last grade completed in school.
Health status measures—We measured patients’ functional
status with the Karnofsky score and Eastern Cooperative
Oncology Group (ECOG) performance status,
18 comorbid
medicalconditionswiththeCharlsonComorbidityIndex,
19and
quality of life with the McGill Quality of Life Index.
20.
Treatmentpreferences,terminalillnessacknowledgment,coping,
communication,andadvancecareplanning—Weusedvalidated
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RESEARCHmeasures to elicit patients’ preferences for chemotherapy,
mechanicalventilation,admissiontoanintensivecareunitnear
death, and life extending care versus comfort care.
21 22 We also
assessed patients’ acknowledgment of terminal illness, as this
has been associated with higher rates of advance care planning
andhospiceuse.
23TheBriefCOPEandRCOPEsurveysassessed
active, emotion focused, maladaptive, and positive religious
coping with cancer related stress.
24 We also asked patients
whethertheyrecalledhavinganendoflifediscussionwiththeir
physician,
11 had a strong therapeutic alliance with their
providers,
25 and had completed a living will, durable power of
attorney, or do not resuscitate order (see web appendix).
Statistical analyses
We used t test, χ
2, and Fisher’s exact statistics, as appropriate,
to test for significant associations between patients’ baseline
characteristics and the receipt of chemotherapy at study
enrollment. We used multiple imputation to impute missing
data for items other than the dependent variables (for which no
data were missing in our cohort)
26; item non-response was less
than 14% for all variables.
We used propensity score analyses to assess the association
betweenpatientswhowereorwerenotreceivingchemotherapy
at the time of enrollment.
27 To do the propensity score analysis,
we first used logistic regression to assess the association of all
measureddemographic,clinical,psychosocial,andinstitutional
characteristicswithbeingtreatedwithchemotherapyatbaseline.
The model included age, sex, marital status, insurance status,
education, race/ethnicity, religion, institution, cancer type,
Karnofsky and ECOG scores, Charlson Comorbidity Index,
McGill Quality of Life Index subscales, patients’ treatment
preferences and advance care planning, terminal illness
acknowledgment, therapeutic alliance with physicians, end of
life discussions, and coping styles. For each patient, we used
the regression coefficients and the observed covariates to
calculate the propensity to receive chemotherapy at study
enrollment and derived individual weights equal to the
probability of belonging to the opposite group (that is, not
receivingchemotherapy).
11 28Thus,afterpropensityadjustment
the weighted distribution of characteristics in both groups were
balanced. We then used a generalized linear regression model
with an identity link function and a binomial distribution, with
the propensity weighted cohorts, to estimate the association of
chemotherapy with binary outcomes (for example,
cardiopulmonary resuscitation and/or mechanical ventilation).
Our events were rare, so we calculated and reported our results
as adjusted risk differences as odds ratios may exaggerate the
actual risk. We did a sensitivity analysis to examine the effect
ofexcludingcovariatesthatmightchangeovertime(Karnofsky
score, ECOG score, McGill Quality of Life scales, treatment
preferences, and terminal illness awareness), as the exact date
of starting palliative chemotherapy was not ascertained during
the baseline assessment. We used Cox proportional hazard
models to compare the overall survival of patients who were
receiving palliative chemotherapy with those who were not,
with adjustment for propensity weights.
We used SOLAS for Missing Data Analysis version 4.0 for
multipleimputationandSASversion9.2forstatisticalanalyses.
We present two sided P values without adjustment for multiple
comparisons; we considered P<0.05 to be significant.
Results
The cohort consisted of 386 terminally ill cancer patients who
died a median of 4.0 (interquartile range 1.8-8.3) months after
enrollment in the study. Overall, 56.0% of participants were
receiving palliative chemotherapy on study enrollment. As
shown in table 1⇓, patients who were receiving palliative
chemotherapyweremorelikelytobeyounger,married,insured,
and better educated and to have better performance status,
overall quality of life, physical functioning, and psychological
wellbeing compared with patients who were not receiving
chemotherapy (all P≤0.04). They were also more likely to
express a preference to receive “life extending” care over
comfort care (39% v 26%, P=0.01), including chemotherapy if
it might extend their life by one week (86% v 60%, P<0.001),
compared with those not receiving chemotherapy.
Patients receiving palliative chemotherapy were less likely to
acknowledge that their illness was terminal (35% v 49%,
P=0.04) and to report having discussed their end of life wishes
with a physician (37% v 48%, P=0.03), compared with those
who were not. They were also less likely to have completed a
donotresuscitateorder(36%v49%,P<0.05).Propensityscore
weightingsuccessfullybalancedalloftheobserveddifferences
in patients’ characteristics between the two groups (table 1⇓).
Inpropensityscoreweightedanalyses,receiptofchemotherapy
at enrollment was associated with significantly more intensive
medicalinterventionsneardeath.Asshownintable2⇓,patients
receiving palliative chemotherapy were more likely to receive
cardiopulmonary resuscitation, mechanical ventilation, or both
in the last week of life (14% v 2%; adjusted risk difference
10.5%,95%confidenceinterval5.0%to15.5%)comparedwith
thosewhowerenot.Chemotherapyusewasalsoassociatedwith
higher rates of use of a feeding tube in the last week (11% v
5%; adjusted risk difference 7.1%, 1.7% to 12.5%) and of late
hospicereferrals(54%v37%enrolledwithinoneweekofdeath;
13.6%, 3.6% to 23.6%). In adjusted Cox proportional hazards
models, we found no significant difference in overall survival
between patients who were receiving palliative chemotherapy
at study enrollment and those who were not (hazard ratio 1.11,
95% confidence interval 0.90 to 1.38). In a secondary model,
we assessed the association between receipt of palliative
chemotherapy and the intensity of end of life medical care
withoutincludingcharacteristicsthatmighthavechangedsince
the decision to start palliative chemotherapy was made (that is,
performance status, quality of life, treatment preferences, and
terminal illness acknowledgment), and the results did not
change.
As shown in table 3⇓, patients who received chemotherapy at
enrollment were more likely to die in an intensive care unit
(11% v 2%; adjusted risk difference 6.1%, 1.1% to 11.1%) and
less likely to die at home (47% v 66%; −10.8%, −1.0% to
−20.6%),comparedwiththosewhowerenot.Patientswhowere
receiving palliative chemotherapy on study enrollment were
alsolesslikelydieintheirpreferredplace,comparedwiththose
who were not (68% v 80%; adjusted risk difference −9.4%,
−0.8% to −18.1%). In a second model, we examined the
associationbetweenpalliativechemotherapyandpatients’place
of death without including characteristics that might change
over time; our results were consistent, except that patients’
likelihood of dying in their preferred place was no longer
statistically significant (P=0.07).
Discussion
Our results suggest that terminally ill patients with advanced
cancers who receive chemotherapy a few months before death
are more likely to receive intensive care at the end of life,
compared with patients who do not. In this study, the use of
chemotherapy a median of 4.0 months before death was
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RESEARCHassociated with an increased risk of undergoing mechanical
ventilation, cardiopulmonary resuscitation, or both in the last
week of life and of being referred to a hospice late, both of
which have been associated with worse quality of life for
patients at the end of life,
11 29 30 more distress in bereaved
caregivers,
11 29 and higher costs.
31 The use of palliative
chemotherapy was also associated with an increased risk of
dying in an intensive care unit, a decreased likelihood of dying
at home, and a lower likelihood that patients died in their
preferred place.
Comparison with other studies
This is the first study, to our knowledge, to examine the
associations between the use of palliative chemotherapy and
patients’ location of death. Whereas previous studies have
identified patient, caregiver, and system level factors that
influence where cancer patients die,
32-34 few have focused on
how the care that terminally ill cancer patients receive in the
final months of life relates to their place of death outside of
hospice or palliative care settings.
35
In this study, only a minority of terminally ill cancer patients
preferred life extending medical care over care that focused on
relievingpainanddiscomfort.However,morethanhalfwanted
chemotherapy if it would extend their life by one week,
including60%ofpatientswhowerenotreceivingchemotherapy.
Thisfindingisconsistentwithpreviousstudiesthathaveshown
that many cancer patients are willing to undergo significant
treatment related toxicities for small objective benefits.
36 37 The
oneweeksurvivalthresholdforchemotherapythatweobserved
is significantly lower than the four to five month thresholds
previously reported in similar populations of patients,
37-39 and
it suggests that cancer patients may not regard chemotherapy
as burdensome because they are willing to receive it for very
limited temporal pay-off.
Ourfindingsalsounderscorethechallengethatmanyoncologists
facewhendiscussingtheoptionofstoppingchemotherapywith
patients and their caregivers,
40 particularly when patients—and
physicians—may equate stopping treatment with “giving up”
or “doing nothing.”
41 42 In this study, we observed significant
differences in the rates of use of chemotherapy by institution,
although they were balanced after propensity weighting and
therefore did not influence the observed associations between
receipt of chemotherapy and patients’ end of life medical care
and place of death. Although our study could not directly
compare the relative influences of patient, provider, and
institution level factors, we suspect that a combination of these
factorsexplainsthedifferencesobserved.Futurestudiesshould
examine the most important determinants of end of life use of
chemotherapy.
Inthisstudy,wedidnotobserveadifferenceinsurvivalbetween
patients who received palliative chemotherapy and those who
didnot.Thisshouldnotbeinterpretedasevidencethatpalliative
chemotherapy is futile in terminally ill cancer patients, as our
analysiswaslimitedtosmallsampleofdecedentsandmayhave
excluded patients who benefited most from chemotherapy.
Instead, this finding should serve as a reminder that palliative
chemotherapydoesnotnecessarilyextendlife,butisassociated
with more intensive end of life care and increased risk of dying
in an intensive care unit, so continuing treatment should not
come at the cost of engaging in advance care planning.
14 15
Strengths and limitations
This study has several important strengths. Previous studies
have found that older patients who received chemotherapy
within two weeks of death had higher rates of emergency
departmentvisitsandhospitaladmissionsanddecreasedhospice
useattheendoflife.
6 7 43Ourdata,collectedmorethanadecade
later, extend these results by examining associations between
palliative chemotherapy given months before death, at the time
when most decision making about chemotherapy occurs, and
the intensity of patients’ end of life medical care and place of
death. Our study may also be more representative of the care
provided to “dying patients” than previous work because it
enrolled patients of all ages who were prospectively identified
by their physicians as terminally ill with a prognosis of six
months or less to live.
44 45 In addition, we had comprehensive
data on patients’ performance status, physical functioning,
quality of life, and many other psychosocial factors associated
with end of life decision making, including patients’ treatment
preferences, awareness of terminal illness, and end of life
discussions with physicians,
11 22 23 46 which are rarely available
in other databases.
The study also has limitations. Most notably, we did not have
anyinformationaboutthetimingornatureofpatients’decisions
about treatment after study enrollment, except for the last week
of life. However, subsequent decisions to resume or stop
chemotherapy would minimize differences between the two
groups, making detection of the effects observed less likely.
Despite this, we observed significant associations between the
useofpalliativechemotherapyandtheintensityofpatients’end
of life care and place of death, and our results did not change
when we removed characteristics that often change in response
tochemotherapy(suchasqualityoflifeandperformancestatus)
or disease progression (such as treatment preferences and
awarenessofterminalillness).However,theassociationbetween
receiptofpalliativechemotherapyandpatients’preferredplace
of death became marginally significant in sensitivity analyses
and when we included additional covariates in propensity
weighted models; thus, future studies should confirm these
results in larger populations.
Inaddition,wedidnothaveinformationaboutpatients’baseline
preferences for the timing of referral to a hospice or place of
death. Although short hospice stays—and treatment in an
intensive care unit near death—may be viewed as beneficial to
dying patients or their family caregivers,
47 our previous work
suggests that for most patients these outcomes are associated
withworsequalityoflifeforpatientsandmoredistressinfamily
caregiverssixmonthsafterbereavement.
11 29Inaddition,wedid
not randomize patients to receive palliative chemotherapy or
not. Whereas propensity score weighting can effectively adjust
for observed differences, it can adjust for unobserved
confounders only if they are associated with observed
confounders. Furthermore, patients who were receiving
chemotherapy at enrollment may have differed in unmeasured
ways from those who were not receiving chemotherapy (for
example, in their disease duration or previous experiences with
chemotherapy).
Finally,ouranalyseswerelimitedtodeceasedpatientswhodied
in2008,andonlyasmallproportionofourpatientsexperienced
theendoflifeoutcomesofinterest.Nevertheless,thefrequency
of events we observed is comparable to or higher than those
from population based studies using the most recent Medicare
claims available. For example, Teno et al found that 6.7% of
cancerpatientsreceivedmechanicalventilationinthelastmonth
of life in 2009.
48 In our study, 8.5% of terminally ill cancer
patients received mechanical ventilation or cardiopulmonary
resuscitationinthelastweekoflife,butasignificantdifference
existed between groups (13.9% v 1.6%) based on exposure to
chemotherapy at baseline. Furthermore, we expect that our
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RESEARCHfindingsmaybeaconservativeestimate,asTenoetalalsofound
that the intensity of medical care near death is increasing over
time.
48
Conclusions and policy implications
Our results suggest that less use of palliative chemotherapy
among patients recognized to have a life expectancy of six
months or less—or more frequent end of life discussions in this
group—mayreduceintensiveendoflifecareandpromoteearlier
access to hospice services, thus improving the quality of
advancedcancerpatients’endoflifecare.Futurestudiesshould
determine the mechanisms by which palliative chemotherapy
is associated with increased risk of receiving intensive care at
the end of life and dying in an intensive care unit and examine
explicitly whether palliative chemotherapy is associated with
patients’ goal attainment.
Our study has important implications for oncology providers,
patients with advanced cancer, and caregivers facing decisions
about treatment. It suggests that end of life discussions may be
particularly important for patients receiving palliative
chemotherapy, who should be informed by data on the likely
outcomes associated with its use. The findings also suggest the
need for oncology providers to elicit patients’ preferred site of
death to ensure that patients’ end of life experiences are
congruent with their values.
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RESEARCHTables
Table 1| Participants’ characteristics by chemotherapy at study enrollment. Values are numbers (percentages) unless stated otherwise
After propensity weighted adjustment Before propensity weighted adjustment
All participants
(n=386) Baseline characteristic* P value
Chemotherapy
P value
Chemotherapy
No (n=170) Yes (n=216) No (n=170) Yes (n=216)
>0.9 57.9 (12.2) 57.9 (11.9) <0.001 61.0 (12.5) 56.4 (12.3) 58.4 (12.5) Mean (SD) age, years
>0.9 (55.8) (55.8) 0.8 96 (56) 119 (55) 215 (56) Male sex
0.8 (58.0) (58.0) 0.04 94 (55) 142 (66) 236 (61) Married
0.8 (55.8) (55.9) 0.02 93 (55) 145 (67) 238 (62) Insured
>0.9 11.9 (4.2) 11.9 (4.1) <0.001 11.6 (4.0) 13.3 (3.9) 12.6 (4.0) Mean (SD) years of
education
0.7 0.1 Race/ethnicity:
(58.7) (58.7) 104 (61) 147 (68) 251 (65) White
(22.1) (22.1) 34 (20) 36 (17) 70 (18) Black
(18.4) (18.4) 31 (18) 26 (12) 57 (15) Hispanic
(0.0) (0.7) 0 (0) 5 (2) 5 (1) Asian
>0.9 0.5 Religion:
(34.6) (34.6) 65 (38) 76 (35) 141 (36) Catholic
(16.0) (16.0) 26 (15) 42 (19) 68 (18) Protestant
(3.4) (3.4) 4 (2) 14 (6) 18 (5) Jewish
(0.7) (0.7) 2 (1) 3 (1) 5 (1) Muslim
(5.0) (6.1) 9 (5) 8 (4) 17 (4) No religion
(1.7) (3.7) 3 (2) 6 (3) 9 (2) Pentecostal
(19.5) (17.0) 29 (17) 29 (13) 58 (15) Baptist
>0.9 <0.001 Institution:
(17.8) (17.8) 17 (10) 58 (27) 75 (19) Yale Cancer Center
(5.7) (5.7) 11 (6) 8 (4) 19 (5) Veterans Affairs CCC
(52.8) (53.3) 82 (48) 106 (49) 188 (49) Parkland and Simmons
Cancer Center
(3.3) (3.3) 2 (1) 26 (12) 28 (7) MSKCC
(3.1) (3.1) 4 (2) 3 (1) 7 (2) Dana-Farber and
Massachusetts General
(16.6) (16.6) 53 (31) 14 (6) 67 (17) New Hampshire Oncology
Hematology
0.9 0.02 Cancer:
(28.2) (23.7) 42 (25) 43 (20) 85 (22) Lung
(8.4) (8.4) 9 (5) 27 (13) 36 (9) Pancreatic
(14.5) (14.5) 19 (11) 38 (18) 57 (15) Colorectal
(13.4) (13.4) 30 (18) 27 (13) 57 (15) Other gastrointestinal
(9.5) (12.4) 15 (9) 27 (13) 42 (11) Breast
(27.5) (27.5) 56 (33) 54 (25) 110 (29) Other†
Mean (SD) performance
status‡:
0.6 65.3 (18.2) 64.5 (12.7) <0.001 59.5 (16.4) 69.0 (14.8) 64.8 (16.2) Karnofsky score
0.9 1.7 (0.9) 1.7 (0.7) <0.001 2.0 (0.9) 1.5 (0.9) 1.7 (0.9) ECOG score
0.8 8.3 (2.7) 8.3 (2.4) 0.002 8.8 (3.0) 7.9 (2.3) 8.3 (2.7) Charlson Comorbidity
Index
Mean (SD) McGill Quality of
Life§:
>0.9 5.6 (3.0) 5.7 (2.3) 0.004 5.3 (2.9) 6.1 (2.4) 5.7 (2.6) Physical functioning
>0.9 5.3 (2.2) 5.3 (1.8) <0.001 4.9 (2.1) 5.8 (2.0) 5.4 (2.1) Symptoms
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RESEARCHTable 1 (continued)
After propensity weighted adjustment Before propensity weighted adjustment
All participants
(n=386) Baseline characteristic* P value
Chemotherapy
P value
Chemotherapy
No (n=170) Yes (n=216) No (n=170) Yes (n=216)
>0.9 7.2 (2.6) 7.2 (2.5) 0.002 6.7 (2.6) 7.6 (2.4) 7.2 (2.5) Psychological:
>0.9 6.3 (3.3) 6.3 (2.9) 0.03 7.0 (3.2) 7.7 (2.7) 7.4 (2.9) Depressed
>0.9 6.8 (3.6) 6.8 (3.1) 0.01 6.4 (3.3) 7.2 (3.0) 6.9 (3.2) Worried
>0.9 6.3 (3.1) 6.3 (3.0) <0.001 6.4 (3.2) 7.9 (2.7) 7.3 (3.0) Sad
>0.9 6.3 (3.5) 6.3 (2.9) 0.2 7.0 (3.4) 7.4 (2.8) 7.2 (3.1) Terrified
0.5 8.6 (1.7) 8.7 (1.6) 0.9 8.7 (1.6) 8.6 (1.7) 8.6 (1.6) Support
>0.9 6.8 (1.6) 6.8 (1.4) 0.002 6.6 (1.6) 7.0 (1.4) 6.8 (1.5) Sum score of quality of life
Treatment preferences and
planning:
0.9 (74.0) (74.4) 0.8 117 (69) 152 (70) 269 (69) Wants prognostic
information
0.9 (29.1) (29.9) 0.01 44 (24) 85 (37) 129 (31) Life extending care over
comfort care
— (79.2) (79.9) <0.001 102 (62) 186 (89) 288 (77) Chemotherapy to extend
life by 1 week
0.9 (37.8) (37.4) 0.1 85 (47) 76 (33) 161 (39) Wants to avoid dying in
ICU
>0.9 (53.0) (52.5) 0.1 103 (61) 111 (51) 214 (55) Completed living will or
DPA
0.8 (40.4) (40.4) <0.05 84 (49) 77 (36) 161 (42) Completed DNR order
>0.9 (39.6) (39.3) 0.04 83 (47) 76 (35) 159 (40) Terminal illness
acknowledgment
Patient-physician
communication:
>0.9 (64.6) (64.4) 0.3 113 (67) 131 (62) 244 (64) Therapeutic alliance with
physician
>0.9 (40.4) (40.4) 0.03 82 (48) 80 (37) 162 (42) Discussed end of life
wishes with physician
Coping style:
0.6 (47.1) (44.7) 0.3 72 (42) 105 (49) 177 (46) Active
0.8 (48.7) (50.0) >0.9 84 (49) 106 (49) 190 (49) Emotional
0.3 (25.7) (21.3) <0.001 51 (30) 31 (14) 82 (21) Behavioral disengagement
0.6 11.8 (7.0) 11.4 (6.1) 0.6 11.0 (6.5) 11.3 (6.3) 11.2 (6.4) Mean (SD) positive religious
coping
CCC=Comprehensive Cancer Clinics; DNR=do not resuscitate; DPA=durable power of attorney; ECOG=Eastern Cooperative Oncology Group; ICU=intensive
care unit; MSKCC=Memorial Sloan Kettering Cancer Center.
*Missing data: age (n=2), male sex (n=2), married (n=6), insurance (n=10), education (n=2), race/ethnicity (n=2), religion (n=2), Karnofsky score (n=20), ECOG
score (n=8), Charlson Comorbidity Index (n=8), McGill Quality of Life (n=4), prognostic information (n=34), chemotherapy to extend life by 1 week (n=42), avoid
death in ICU (n=40), living will or DPA (n=40), DNR order (n=38), terminal illness acknowledgment (n=40), therapeutic alliance with physician (n=31), end of life
wishes (n=1), positive religious coping (n=51); multiple imputation was used to impute missing values in propensity weighted sample.
†Remaining patients had cancers that each represented ≤5% of sample.
‡Karnofsky score is a measure of functional status that is predictive of survival (0=dead and 100=perfect health); ECOG score is a measure of functional status
(0=asymptomatic and 5=dead); Charlson comorbidity index is an age adjusted measure of comorbid illness (higher numbers signify greater burden).
§Subscales of McGill Quality of Life Questionnaire (scale 0-10), where 0 is undesirable and 10 is desirable; for consistency, individual items where 10 indicated
undesirable states (for example, 0=not at all depressed and 10=extremely depressed) were re-scaled.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;348:g1219 doi: 10.1136/bmj.g1219 (Published 4 March 2014) Page 8 of 10
RESEARCHTable2|Associationsbetweenchemotherapyatstudyenrollmentandintensityofendoflifecare.Valuesarenumbers(percentages)unless
stated otherwise
Propensity weighted adjusted analysis Unadjusted analysis
Medical care in last
week* P value
Risk difference
(95% CI)
Chemotherapy at enrollment
Risk difference
(95% CI)
Chemotherapy at enrollment
No Yes No (n=170) Yes (n=216)
<0.001 10.5 (5.0 to15.5) 4 (2) 24 (12) 12.1 (7.1 to 17.1) 3 (2) 30 (14) Cardiopulmonary
resuscitation,
ventilation, or both
0.07 5.6 (−0.5 to 11.7) 15 (8) 26 (13) 6.1 (−0.2 to 7.4) 14 (8) 31 (14) Admission to intensive
care unit
0.7 1.1 (−3.6 to 5.7) 10 (5) 12 (6) 2.7 (−2.0 to 7.4) 8 (5) 16 (7) Chemotherapy
0.01 7.1 (1.7 to 12.5) 9 (5) 22 (12) 5.3 (−0.1 to 10.7) 9 (5) 23 (11) Feeding tube for
enteral nutrition
0.008 13.6 (3.6 to 23.6) 70 (38) 96 (52) 17.6 (7.6 to 27.6) 61 (37) 113 (54) Hospice ≤1 week
*Missing data: admission to intensive care unit (n=1, no chemotherapy), feeding tube for enteral nutrition (n=4; n=1 chemotherapy, n=3 no chemotherapy), and
hospice ≤1 week (n=12; n=8 chemotherapy, n=4 no chemotherapy).
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RESEARCHTable 3| Associations between chemotherapy at study enrollment, place of death, and attainment of preferred place of death. Values are
numbers (percentages) unless stated otherwise
Propensity weighted adjusted analysis Unadjusted analysis
Variable* P value
Risk difference (95%
CI)
Chemotherapy at enrollment
Risk difference (95%
CI)
Chemotherapy at enrollment
No Yes No (n=170) Yes (n=216)
Place of death:
0.02 6.1 (1.1 to 11.1) 7 (4) 19 (10) 8.8 (4.0 to 13.6) 4 (2) 24 (11) Intensive care unit
0.4 3.6 (−4.1 to 11.3) 32 (17) 38 (21) 9.8 (1.9 to 17.8) 26 (15) 54 (25) Hospital
0.03 −10.8 (−1.0 to −20.6) 122 (63) 100 (52) −18.4 (−8.7 to −28.2) 112 (66) 102 (47) Home
0.6 2.0 (−4.6 to 8.7) 22 (12) 26 (13) −1.8 (−4.7 to −8.4) 19 (11) 28 (13) Inpatient hospice
0.6 1.0 (−5.0 to 3.1) 9 (5) 7 (4) −2.0 (−6.2 to 2.1) 9 (5) 7 (3) Nursing home
0.03 −9.4 (−0.8 to −18.1) 154 (80) 131 (68) −12.4 (−3.6 to −21.2) 135 (80) 140 (65) Death in preferred
place
*Missing data: place of death (n=1, chemotherapy), death in preferred place (n=12; n=10 chemotherapy, n=2 no chemotherapy).
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;348:g1219 doi: 10.1136/bmj.g1219 (Published 4 March 2014) Page 10 of 10
RESEARCH